XORTX Sponsored Study Presented at the American Society of Nephrology – Kidney Week 2024
October 24 2024 - 7:00AM
XORTX Therapeutics Inc. ("
XORTX" or the
“
Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt:
ANU), a late-stage clinical pharmaceutical company focused on
developing innovative therapies to treat progressive kidney
disease, is pleased to announce the acceptance of an abstract
submitted to the American Society of Nephrology (the “ASN”).
The abstract entitled
"Xanthine oxidase in rats, mice and
humans with polycystic kidney disease" was reviewed by the
ASN review panel for scientific merit and novel discoveries.
The study was conducted at the University of Colorado in the
independent laboratory of Dr. Charles Edelstein and was sponsored
by XORTX and will be presented during the Session Title: Genetic
Diseases: Cystic - Therapeutic Investigations and
Prognosis. Selected results from the study include:
In both Rat or Mouse models of
Polycystic Kidney Disease (“PKD”)
i) Use of
a uricase inhibitor to increase uric acid resulted in increased
cyst growthii) Xanthine oxidase (“XO”) inhibitor – Oxypurinol
– decreased serum uric acid and cyst growthiii) Increased XO
staining in kidney and liver was abundant
Prospective /
Retrospective Clinical Results of the Halt Clinical Trial - Group A
- Early PKD patients
iv) Patients with
increased serum uric acid had increased total kidney volumev)
Patients with increased serum uric acid had faster PKD
progressionvi) Increase serum XO activity was associated with an
earlier onset of high blood pressure
About this
Study
The XO enzyme is an essential enzyme within the
uric acid pathway, and is required for the breakdown of purine
nucleotides. Uric acid as well as reactive oxygen species released
during the enzymatic reaction may also play a detrimental role in
the circulatory system and within tissue during disease. Recent
pioneering discoveries in rodent models of PKD implicate over
expression or over activity of XO. It is currently unknown if XO
over expression or over activity in humans is associated with PKD
or more rapid progression of disease. The aim of the study was to
gain insight into whether increased XO activity results in cyst
growth, XO activity was measured in PCK1 rats, PKD1RC/RC (RC) mice
and 34 patients from the HALT-PKD Clinical study.
The abstract outlines study results from rat,
mice and human studies of PKD. The purpose of the study was to gain
and understanding of serum xanthine oxidase activity (XOa) in PKD
during varied stages of disease and further to relate that activity
to total kidney volume, and decline of glomerular filtration rate
(GFR). The results of the study provide understanding of
where aberrant purine metabolism in PKD tissue due to sources XO
enzyme may contribute to circulating uric acid levels, expansion
rate of kidney and cyst and functional GFR decline. Prior
study results suggested over expression of XO in PKD kidney tissue
may be a feature of cystic disease.
Dr. Allen Davidoff, CEO of XORTX commented,
“Exploring and understanding the contribution of chronically
increased serum uric acid and/or the effect of too much or too
active XO enzyme in the circulation or tissue on PKD disease
progression was a goal of this study. The study results presented
today are another pioneering first step towards characterizing how
and when to treat individuals with PKD as well as how they might
benefit from the Company’s XRx-008 program, and our upcoming
registration clinical trial. This study was a preliminary
investigation of individuals with early stage PKD, and provided
information regarding the health consequences of hyperuricemia and
XO. The Company will continue to add to this exciting discovery
with future exploration of later stage PKD, assessment of genetic
factors contributing to aberrant purine metabolism, including XO
overexpression, and this precision medicine opportunity.”
About XORTX
Therapeutics Inc.
XORTX is a
pharmaceutical company with two clinically advanced products in
development: 1) our lead, XRx-008 program for ADPKD; and 2) our
secondary program in XRx-101 for acute kidney and other acute organ
injury associated with Coronavirus / COVID-19 infection. In
addition, XRx-225 is a pre-clinical stage program for Type 2
Diabetic Nephropathy. XORTX is working to advance its clinical
development stage products that target aberrant purine metabolism
and xanthine oxidase to decrease or inhibit production of uric
acid. At XORTX, we are dedicated to developing medications to
improve the quality of life and health of kidney disease patients.
Additional information on XORTX is available at www.xortx.com.
For more
information, please contact: |
|
|
|
Allen Davidoff, CEO |
Nick Rigopulos, Director of Communications |
adavidoff@xortx.com or +1 403 455 7727 |
nick@alpineequityadv.com or +1 617 901 0785 |
|
|
Neither the TSX
Venture Exchange nor Nasdaq has approved or disapproved the
contents of this news release. No stock exchange, securities
commission or other regulatory authority has approved or
disapproved the information contained herein.
Forward
Looking Statements
This press release
contains express or implied forward-looking statements pursuant to
applicable securities laws. These forward-looking statements
include, but are not limited to, the Company's beliefs, plans,
goals, objectives, expectations, assumptions, estimates,
intentions, future performance, other statements that are not
historical facts and statements identified by words such as
"expects", "anticipates", "intends", "plans", "believes", "seeks",
"estimates" or words of similar meaning. These forward-looking
statements and their implications are based on the current
expectations of the management of XORTX only, and are subject to a
number of factors and uncertainties that could cause actual results
to differ materially from those described in the forward-looking
statements. Such risks, uncertainties, and other factors include,
but are not limited to, our ability to obtain additional financing;
the accuracy of our estimates regarding expenses, future revenues
and capital requirements; the success and timing of our preclinical
studies and clinical trials; the performance of third-party
manufacturers and contract research organizations; our plans to
develop and commercialize our product candidates; our plans to
advance research in other kidney disease applications; and, our
ability to obtain and maintain intellectual property protection for
our product candidates. Except as otherwise required by applicable
law and stock exchange rules, XORTX undertakes no obligation to
publicly release any revisions to these forward-looking statements
to reflect events or circumstances after the date hereof or to
reflect the occurrence of unanticipated events. More detailed
information about the risks and uncertainties affecting XORTX is
contained under the heading “Risk Factors” in XORTX’s Annual Report
on Form 20-F filed with the SEC, which is available on the SEC's
website, www.sec.gov (including any documents forming a part
thereof or incorporated by reference therein), as well as in our
reports, public disclosure documents and other filings with the
securities commissions and other regulatory bodies in Canada, which
are available on www.sedarplus.ca.
Xortx Therapeutics (TSXV:XRTX)
Historical Stock Chart
From Nov 2024 to Dec 2024
Xortx Therapeutics (TSXV:XRTX)
Historical Stock Chart
From Dec 2023 to Dec 2024